initi coverag outperform
number map major
celebr new year andexxa approv
analyst certif import disclosur see
number map major
analyt collabor infrastructur softwar
twilio remain one top pick bullish thesi predic strong still underappreci core growth support
grow usage/adopt revenu synergi sendgrid potenti flex contribut grow avail number
larg use case contact center iot field services/logist marketing/custom journey autom enabl bundling/integr
platform compon longer term gross margin expans potenti twilio stock expens rel consensu estim
layer upsid opportun valu stock ev/sal closer slower-growth peer given twilio leadership posit
focu enabl applic commun better custom experi believ twilio outperform even volatil market
initi coverag outperform
initi coverag clinical-stag biotechnolog compani develop messeng rna mrna address
infecti diseas cancer rare diseas outperform rate month target price anticip
decemb ipo commerci first development-stag drug
celebr new year andexxa approv
announc fda approv prior approv supplement pa large-scal andexxa allow
broad commerci launch us andexxa initi approv may fda acceler approv pathway
launch andexxa earli suppli program product hospit major trauma center trial site pa approv
today launch eventu expand center us indic call andexxa
tier institut ultim plan priorit view pa approv import first step turnaround andexxa
launch maintain price target
emerg technolog servic
curiou winstonth super-intellig gorillaoften say videogam overwatch also came mind activis
blizzard file decemb indic compani intend fire cfo spencer neumann caus immedi
also indic reason unrel financi report account disclosures/procedur final file indic mr neumann
would put paid leav abl prove caus unjustifi next day reuter link report prepar hire mr
neumann next cfo like breach employ contract coven quit frankli see posit
compani leadership found compani becom corpor move away etho made activis
blizzard strong link re-instal denni durkin cfo role provid stabil chanc compani rebal creativ
monetizationsometh believ gone awri mr neumann leadership reiter ourperform rate
conduct physician survey better understand treatment option heart failur survey design gain insight
current use avail treatment option chronic acut heart failur well potenti use relaxin becom fda
approv survey examin differ type heart failur patient adequaci current prescrib treatment likelihood
prescrib potenti relaxin treatment chronic acut heart failur patient
conduct physician survey better understand treatment option infecti diseas primarili respiratori syncyti viru rsv
cytomegaloviru cmv survey design gain insight current use avail treatment option rsv cmv well
potenti use mrna vaccin becom fda approv survey examin familiar mrna vaccin breakdown
current prescrib treatment rsv cmv likelihood prescrib potenti mrna vaccin rsv cmv
updat analysi perform valuat use data past year use previous deriv rel valuat
model believ biotechnolog sector continu under-valued level importantli continu believ biggest
potenti catalyst increas rel valu sector would increas expect earn growth
discontinu research coverag previous rate perform due realloc analyst resourc
discontinu research coverag cti biopharma ctic previous rate outperform due realloc analyst resourc
discontinu research coverag cytomx previous rate perform due realloc analyst resourc
discontinu research coverag verastem vstm previous rate outperform due realloc analyst resourc
discontinu research coverag previous rate outperform pt due realloc analyst resourc
decis unrel awar part materi chang fundament condit oper
continu cover would necessarili consid chang rate time
june summit emerg biotechnolog montauk ny
